Targeted Therapy

FDA Approves Early Access to Breakthrough Pancreatic Cancer Drug, First RAS Inhibitor Shows Promise

The FDA approves expanded access to daraxonrasib, the first RAS-targeting inhibitor for pancreatic cancer, which has shown promise in extending survival for metastatic patients in clinical trials.

FDA Expands Access to Promising Pancreatic Cancer Drug daraxonrasib

The FDA has granted expanded access to Revolution Medicines’ targeted pancreatic cancer drug daraxonrasib, opening a pathway for more patients to receive a therapy that has shown promising results in clinical trials.

FDA Grants Expanded Early Access to Pancreatic Cancer Drug Daraxonrasib

The U.S. FDA approves expanded early access for the experimental pancreatic cancer drug daraxonrasib, offering new hope for late-stage patients.